Over de diagnostiek bij onregelmatig bloedverlies bij postmenopauzale vrouwen die continue combinatietherapie gebruiken, bestaat weinig consensus in (internationale) richtlijnen. 769697
Onregelmatig bloedverlies (bloedverlies buiten de maandelijkse onttrekkingsbloedingen) bij postmenopauzale vrouwen die sequentiële combinatietherapie gebruiken, is reden voor verwijzing voor aanvullende diagnostiek (Landelijke Transmurale Afspraak Vaginaal bloedverlies in de postmenopauze). Als aanvullend onderzoek dient er bij postmenopauzale vrouwen die
onregelmatig bloedverlies hebben bij gebruik van combinatietherapie altijd een cervixuitstrijkje te worden verricht en dient een chlamydia-infectie te zijn uitgesloten.
Referenties
Heineman MJ, Evers JLH, Massuger LFAG, Steegers EAP. Obstetrie en gynaecologie. De voortplanting van de mens. 1.
6e dr. Maarssen: Elsevier Gezondheidszorg, 2007.
WHO. Research on the menopause in the 1990s. Report of WHO Scientific Group (1996). Ga naar bron: WHO.
2.
Research on the menopause in the 1990s. Report of WHO Scientific Group (1996).
Hale GE, Burger HG. Hormonal changes and biomarkers in late reproductive age, menopausal transition and 3.
menopause. Best Pract Res Clin Obstet Gynaecol 2009;23:7-23.
Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W et al. Executive summary: Stages of Reproductive 4.
Aging Workshop (STRAW). Fertil Steril 2001;76:874-8. Nelson HD. Menopause. Lancet 2008;371:760-70. 5.
De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010;376:911-21. 6.
Van de Lisdonk EH, Van den Bosch WJHM, Lagro-Janssen ALM. Ziekten in de huisartspraktijk. 5th. ed. Maarssen: 7.
Elsevier Gezondheidszorg, 2008.
Stirbu-Wagner I, Dorsman SA,Visscher S, Davids R, Gravestein JV, Abrahamse H et al. Landelijk Informatienetwerk 8.
Huisartsenzorg. Feiten en cijfers over huisartsenzorg in Nederland. Utrecht/Nijmegen: NIVEL/IQ, 2010. Geraadpleegd
februari 2012. Ga naar bron: Stirbu-Wagner I, Dorsman SA,Visscher S, Davids R, Gravestein JV, Abrahamse H et al.
Landelijk Informatienetwerk Huisartsenzorg. Feiten en cijfers over huisartsenzorg in Nederland. Utrecht/Nijmegen: NIVEL/IQ, 2010. Geraadpleegd februari 2012.
Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27. 9.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen 10.
plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
De Jong-van den Berg L, Faber A, Van den Berg PB. HRT use in 2001 and 2004 in The Netherlands--a world of 11.
difference. Maturitas 2006;54:193-7.
Lagro-Janssen A, Knufing MW, Schreurs L, Van Weel C. Significant fall in hormone replacement therapy prescription 12.
in general practice. Fam Pract 2010;27:424-9.
Van Disseldorp J, Faddy MJ, Themmen AP, De Jong FH, Peeters PH, Van der Schouw YT et al. Relationship of serum 13.
antimullerian hormone concentration to age at menopause. J Clin Endocrinol Metab 2008;93:2129-34. Kok HS, Van Asselt KM, Van der Schouw YT, Grobbee DE, Te Velde ER, Pearson PL et al. Subfertility reflects 14.
accelerated ovarian ageing. Hum Reprod 2003;18:644-8.
Groeneveld FP, Bareman FP, Barentsen R, Dokter HJ, Drogendijk AC, Hoes AW. The climacteric and well-being. J 15.
Psychosom Obstet Gynaecol 1993;14:127-43.
Parente RC, Faerstein E, Celeste RK, Werneck GL. The relationship between smoking and age at the menopause: A 16.
systematic review. Maturitas 2008;61:287-98.
Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA, Harlow SD, Skurnick J.Factors associated with age at 17.
natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001;153:865-74.
Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen 18.
Intern Med 2008;23:1507-13.
Nelson HD, Haney E, Humphrey L, Miller J, Nedrow A, Nicolaidis C et al. Management of menopause-related 19.
symptoms. 120, 1-916. 2005. Rockville, Agency for Healthcare Research and Quality. Burger H. The menopausal transition--endocrinology. J Sex Med 2008;5:2266-73. 20.
Rebbeck TR, Su HI, Sammel MD, Lin H, Tran TV, Gracia CR et al. Effect of hormone metabolism genotypes on steroid 21.
hormone levels and menopausal symptoms in a prospective population-based cohort of women experiencing the menopausal transition. Menopause 2010;17:1026-34.
Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 22.
1994;29:319-36.
Sturdee DW. The menopausal hot flush--anything new? Maturitas 2008;60:42-9. 23.
Szmuilowicz ED, Manson JE, Rossouw JE, Howard BV, Margolis KL, Greep NC et al. Vasomotor symptoms and 24.
cardiovascular events in postmenopausal women. Menopause 2011;18:603-10.
Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Powell LH, Matthews KA. Hot flashes and carotid intima 25.
media thickness among midlife women. Menopause. 2011 Apr;18(4):352-58.
Allison MA, Manson JE, Aragaki A, Langer RD, Rossouw J, Curb D et al.Vasomotor symptoms and coronary artery 26.
calcium in postmenopausal women. Menopause 2010;17:1136-45.
Ayers B, Forshaw M, Hunter MS. The impact of attitudes towards the menopause on women's symptom experience: a 27.
systematic review. Maturitas 2010;65:28-36.
Berecki-Gisolf J, Begum N, Dobson AJ. Symptoms reported by women in midlife: menopausal transition or aging? 28.
Menopause 2009;16:1021-29.
Pien GW, Sammel MD, Freeman EW, Lin H, DeBlasis TL. Predictors of sleep quality in women in the menopausal 29.
DeLamater J, Karraker A. Sexual functioning in older adults. Curr Psychiatry Rep 2009;11:6-11. 30.
Lindau ST, Gavrilova N. Sex, health, and years of sexually active life gained due to good health: evidence from two US 31.
population based cross sectional surveys of ageing. BMJ 2010;340:c810.
Avis NE, Brockwell S, Randolph JF, Jr., Shen S, Cain VS, Ory M et al. Longitudinal changes in sexual functioning as 32.
women transition through menopause: results from the Study of Women's Health Across the Nation. Menopause 2009;16:442-52.
Van Lunsen RH, Laan E. Genital vascular responsiveness and sexual feelings in midlife women: psychophysiologic, 33.
brain, and genital imaging studies. Menopause 2004;11:741-8.
Laan E, Van Lunsen RH. Hormones and sexuality in postmenopausal women: a psychophysiological study. J Psychosom 34.
Obstet Gynaecol 1997;18:126-33.
Laan E, Van Driel E, Van Lunsen RHW. Sexual responses of women with sexual arousal disorder to visual stimuli. 35.
Tijdschr Seksuol 2003;27:1-13.
Potter JE. A 60-year-old woman with sexual difficulties. JAMA 2007;297:620-33. 36.
Vesco KK, Haney EM, Humphrey L, Fu R, Nelson HD. Influence of menopause on mood: a systematic review of cohort 37.
studies. Climacteric 2007;10:448-65.
De Klerk BM, Schiphof D, Groeneveld FP, Koes BW, Van Osch GJ, Van Meurs JB et al. No clear association between 38.
female hormonal aspects and osteoarthritis of the hand, hip and knee: a systematic review. Rheumatology (Oxford) 2009;48:1160-5.
Mansfield PK, Carey M, Anderson A, Barsom SH, Koch PB. Staging the menopausal transition: data from the TREMIN 39.
Research Program on Women's Health. Womens Health Issues 2004;14:220-6.
McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-15. 40.
Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J 41.
Fertil 1967;12:77-126.
Taffe J, Dennerstein L. Time to the final menstrual period. Fertil Steril 2002;78:397-403. 42.
Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flashes. Maturitas 1997;27:203-14. 43.
Faughnan M, Lepage R, Fugere P, Bissonnette F, Brossard JH, D'Amour P. Screening for thyroid disease at the 44.
menopausal clinic. Clin Invest Med 1995;18:11-8.
Van der Linden MW, Westert GP, De Bakker DH, Schellevis FG. Tweede Nationale Studie naar ziekten en 45.
verrichtingen in de huisartspraktijk: klachten en aandoeningen in de bevolking en in de huisartspraktijk. Utrecht/Bilthoven: NIVEL/RIVM, 2004.
Van der Feltz-Cornelis CM. Therapieresistentie opvliegers bij vrouwen in de overgang: paniekstoornis? Ned Tijdschr 46.
Geneeskd 2001;281-4.
McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-47.
analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-69.
Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast 48.
cancer. J Natl Cancer Inst 2010 Aug 18;102:1224-37.
Lambalk CB, Van Disseldorp J, De Koning CH, Broekmans FJ. Testing ovarian reserve to predict age at menopause. 49.
Maturitas 2009;63:280-91.
Bastian LA, Smith CM, Nanda K. Is this woman perimenopausal? JAMA 2003;289:895-902. 50.
Kahwati LC, Haigler L, Rideout S, Markova T. What is the best way to diagnose menopause? J Fam Pract 51.
2005;54:1000-2.
NABON. Richtlijn Mammacarcinoom (2012). Geraadpleegd januari 2012. Ga naar bron: NABON. Richtlijn
52.
Mammacarcinoom (2012). Geraadpleegd januari 2012.
Van Rossum MM, van der Avoort IAM, de Hoop D, Dukel L, van der Vleuten CJM, de Hullu JA. Lichen sclerosus. Ned 53.
Tijdschr Geneeskd 2007;151:1225-31.
Smith YR, Haefner HK. Vulvar lichen sclerosus : pathophysiology and treatment. Am J Clin Dermatol 2004;5:105-25. 54.
Van der Meerendonk HW, Van Hunsel FP, Van der Wiel HW. Auto-immuun hepatitis door zilverkaars bijwerking van 55.
kruidenextract. Ned Tijdschr Geneeskd 2009;153:246-49.
Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal 56.
symptoms. Cochrane Database Syst Rev 2007;CD001395.
Anonymus. Herbal medicines for menopausal symptoms. Drug Ther Bull 2009;47:2-6. 57.
Commissie Farmaceutische Hulp. Farmacotherapeutisch Kompas 2011. Ga naar bron: Commissie Farmaceutische
58.
Hulp. Farmacotherapeutisch Kompas 2011.
Huang AJ, Subak LL, Wing R, West DS, Hernandez AL, Macer J, et al. An intensive behavioral weight loss intervention 59.
and hot flushes in women. Arch Intern Med 2010;170:1161-7. Ga naar bron: Huang AJ, Subak LL, Wing R, West DS,
Hernandez AL, Macer J, et al. An intensive behavioral weight loss intervention and hot flushes in women. Arch Intern Med 2010;170:1161-7.
MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus 60.
placebo for hot flushes. Cochrane Database Syst Rev 2004;CD002978.
Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 61.
Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie. Informatorium Medicamentorum. Den Haag: 62.
KNMP, 2012.
Farquhar C, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q. Long term hormone therapy for perimenopausal and 63.
postmenopausal women. Cochrane Database Syst Rev 2009;CD004143.
Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R et al. Health risks and benefits 3 years after 64.
stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45.
Canonico M, Plu-Bureau, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism 65.
in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-31.
Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast 66.
cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer 2010;126:483-9.
Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting 67.
hormone therapy. J Natl Cancer Inst 2011;103:296-305.
Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M. Hormone replacement therapy and breast cancer in former 68.
users of oral contraceptives--The Norwegian Women and Cancer study. Int J Cancer 2007;121:645-8.
Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M, Hendrix SL et al. Estrogen plus progestin therapy 69.
and breast cancer in recently postmenopausal women. Am J Epidemiol 2008;167:1207-16.
Vandenbroucke JP. The HRT controversy: observational studies and RCTs fall in line. Lancet 2009;373:1233-35. 70.
Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH et al. Estrogen plus progestin and breast 71.
cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92.
LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L et al. Health outcomes after stopping 72.
conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14.
Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of 73.
stroke: a nested case-control study. BMJ 2010;340:c2519.
Furness S, Roberts H, Marjoribanks J, Lethaby A, Hickey M, Farquhar C. Hormone therapy in postmenopausal women 74.
and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2009;CD000402.
Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 75.
2005;365:1543-51.
NVOG. Richtlijn Diagnostiek bij abnormaal vaginaal bloedverlies in de postmenopauze (2005). Geraadpleegd december 76.
2011. Ga naar bron: NVOG. Richtlijn Diagnostiek bij abnormaal vaginaal bloedverlies in de postmenopauze (2005).
Geraadpleegd december 2011.
Al Kadri H, Hassan S,Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgicalmenopause. Cochrane 77.
Database of Syst Rev 2009: CD005997.
Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or 78.
sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83:686-92.
Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal 79.
women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004;CD000402. Burbos N, Morris E. Menopausal symptoms. ClinicalEvidence 2009;2:804-67.
80.
Hammar ML, Van de Weijer P, Franke HR, Pornel B, Von Mauw EM, Nijland EA. Tibolone and low-dose continuous 81.
combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG 2007;114:1522-9. Nijland EA, Weijmar Schultz WC, Nathorst-Boos J, Helmond FA, Van Lunsen RH, Palacios S et al. Tibolone and 82.
transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008;5:646-56.
Kenemans P, Bundred NJ, Foidart JM, Kubista E, Von Schoultz B, Sismondi P et al. Safety and efficacy of tibolone in 83.
breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135-46.
Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P et al. The effects of tibolone in older 84.
postmenopausal women. N Engl J Med 2008;359:697-708.
Anonymus. Faculty of Sexual & Reproductive Healthcare. Contraception for women aged over 40 years (2010). Ga
85.
naar bron: Anonymus. Faculty of Sexual & Reproductive Healthcare. Contraception for women aged over 40 years (2010).
Gebbie AE, Glasier A, Sweeting V. Incidence of ovulation in perimenopausal women before and during hormone 86.
replacement therapy. Contraception 1995;52:221-2.
Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri- and postmenopausal women. Contraception 87.
2007;75:S155-S160.
Lindh-Astrand L, Bixo M, Hirschberg AL, Sundstrom-Poromaa I, Hammar M. A randomized controlled study of taper-88.
down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. Menopause 2010;17:72-9.
Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J et al. Nonhormonal therapies for menopausal hot flashes: 89.
Loprinzi CL, Sloan J, Stearns V, Slack R, Iyengar M, Diekmann B et al. Newer antidepressants and gabapentin for hot 90.
flashes: an individual patient pooled analysis. J Clin Oncol 2009;27:2831-7.
Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC et al. Selective serotonin reuptake inhibitors 91.
and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693. Bijl D. Overlijden aan mammacarcinoom door interactie SSRI's en tamoxifen. Geneesmiddelen Bulletin 2010;44:45-6. 92.
Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H et al. Efficacy of escitalopram for hot flashes in 93.
healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267-74.
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database 94.
Syst Rev 2010;CD001500.
Weiderpass E, Baron JA, Adami HO, Magnusson C, Lindgren A, Bergstrom R et al. Low-potency oestrogen and risk of 95.
endometrial cancer: a case-control study. Lancet 1999;353:1824-8.
SIGN. Guideline no.61 Investigation of post-menopausal bleeding (2002). Geraadpleegd december 2011. Ga naar bron:
96.
SIGN. Guideline no.61 Investigation of post-menopausal bleeding (2002). Geraadpleegd december 2011.
NICE. Clinical Guideline 27. Referral guidelines for suspected cancer (2005). Geraadpleegd december 2011. Ga naar
97.